Statistics

Total Visits

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone99

Select a period of time:

Number of views in the range

Views
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone51

Views

Views
February 20255
March 202511
April 20255
May 20253
June 20257
July 202520
August 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States25
Singapore6
Brazil6
United Kingdom3
Mexico2
South Africa2
Spain2
Argentina1
Ecuador1
Kenya1
 

Top cities views

Views
Albuquerque1
Ambato1
Atakum1
Cantagalo1
Cape Town1
Council Bluffs1
Dallas1
Goiânia1
Huntingdon1
Itobi1